- Paolo Bruzzi, National Cancer Research Institute
- Ian Cree, Warwick Medical School, Coventry
- Shoukat Dedhar, British Columbia Cancer Agency
- John A Hartley, University College London
- Manami Inoue, University of Tokyo
- Ferdinando Mannello, University Carlo Bo of Urbino
- Christophe Nicot, Kansas University Medical Center
- Stephen P Povoski, The Ohio State University
- Charles Rosser, University of Hawaii Cancer Center
- Dirk Vordermark, Martin Luther University Halle-Wittenberg
- Dafne Solera, BioMed Central
The levels of four urinary miRNAs that are specifically altered in breast cancer patients compared to healthy controls may serve as potential non-invasive innovative biomarkers to detect primary breast cancer.
Nicola Normanno and Ian Cree comment on the role of genomics in oncology, and the issues to overcome before targeted treatment based on genomic profile can become routinely accessible to lung cancer patients.
Cancers of unknown primary origin (CUP) exhibit distinct molecular features compared to metastases of known origin and display signatures of chromosome instability which may account for their uncommon clinical presentation and poor outcome.
A higher maximum of standardized uptake value (SUVmax) on 18F-FDG PET is associated with elevated tumor levels of pAkt and pS6 protein and with aggressive behavior and metastatic potential of renal cell carcinoma (RCC).
A gene panel developed for ion semi-conductor sequencing for the genotyping of colon and lung cancer allows the fast, cost-effective and accurate stratification of patients in a clinical settings.
Analysis of cancer incidence data in England reveals that risk of breast and gynaecological cancers varies by ethnic group but groups typically grouped together are not homogenous with regards to their cancer risk.
Benjamin Jackson and colleagues review our current understanding of the functional consequences of microRNA dysregulation in the development of prostate cancer, and the identification of potential microRNA targets as serum biomarkers.
The overexpression in breast cancer cells of Amyloid-beta precursor protein (APP), involved in Alzheimer’s disease, is linked to tumorigenicity and invasion, and APP may serve as a target for breast cancer therapy.
BMC Cancer is an open access, peer-reviewed journal that considers articles on all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers. The journal welcomes submissions concerning molecular and cellular biology, genetics, epidemiology, and clinical trials.
BMC Cancer is part of the BMC series which publishes subject-specific journals focused on the needs of individual research communities across all areas of biology and medicine. We offer an efficient, fair and friendly peer review service, and are committed to publishing all sound science, provided that there is some advance in knowledge presented by the work.
BMC series - open, inclusive and trusted.
Christudas Morais, David W Johnson, David A Vesey, and Glenda C Gobe1BMC Cancer 2013, 13:14 (10 January 2013)
BMC series blog
- 15 April 2015
- Stillbirth: the elephant in the room
Volume 15 Suppl 1 (15 January 2015)
Research and Reviews
Jeddah, Kingdom of Saudi Arabia. 24-27 November 2013